Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Pulford, Bruce ^a   Reim, Natalia ^a   Bell, Aimee ^a   Veatch, Jessica ^a   Forster, Genevieve ^a   Bender, Heather ^a   Meyerett, Crystal ^a   Hafeman, Scott ^a   Michel, Brady ^a   Johnson, Theodore ^a   Wyckoff, Christy ^a   Miele, Gino ^b   Julius, A Christian ^a   Kranich, Jan ^c   Schenkel, Alan ^a   Dow, Steven ^a   Zabel, Mark D ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; LIPOSOME; MESSENGER RNA; PEPTIDE DERIVATIVE; PRION PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL CULTURE; CELL LINE; COMPLEX FORMATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENSITOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRION DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA SEQUENCE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; PRION;

LENTIVIRUS; MUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOOD-BRAIN BARRIER; CELL LINE; CELLS, CULTURED; LIPOSOMES; MICE; MOLECULAR SEQUENCE DATA; NEURONS; PRIONS; RNA, SMALL INTERFERING;

EID: 77956205950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011085     Document Type: Article

References (71)

1. Bolton DC, McKinley MP, Prusiner SB (1982) Identification of a protein that purifies with the scrapie prion. Science 218: 1309-1311.
2. McKinley MP, Bolton DC, Prusiner SB (1983) A protease-resistant protein is a structural component of the scrapie prion. Cell 35: 57-62.
3. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
4. Beck E, Daniel PM, Matthews WB, Stevens DL, Alpers MP, et al. (1969) Creutzfeldt-Jakob disease. The neuropathology of a transmission experiment. Brain 92: 699-716.
5. Beck E, Daniel PM, Parry HB (1964) Degeneration of the cerebellar and hypothalamo-neurohypophysial systems in sheep with scrapie; and its relationship to human system degenerations. Brain 87: 153-176.
6. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, et al. (1998) Role of microglia in neuronal cell death in prion disease. Brain Pathol 8: 449-457.
7. Giese A, Groschup MH, Hess B, Kretzschmar HA (1995) Neuronal cell death in scrapie-infected mice is due to apoptosis. Brain Pathol 5: 213-221.
8. Büeler HR, Aguzzi A, Sailer A, Greiner RA, Autenried P, et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347.
9. Manson JC, Clarke AR, McBride PA, McConnell I, Hope J (1994) PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3: 331-340.
10. Sailer A, Büeler H, Fischer M, Aguzzi A, Weissmann C (1994) No propagation of prions in mice devoid of PrP. Cell 77: 967-968.
11. Bueler H, Raeber A, Sailer A, Fischer M, Aguzzi A, et al. (1994) High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1: 19-30.
12. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, et al. (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116: 3204-3210.
13. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, et al. (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 105: 10238-10243.
14. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874.
15. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
16. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, et al. (2002) RNA interference in adult mice. Nature 418: 38-39.
17. Paddison PJ, Caudy AA, Hannon GJ (2002) Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A 99: 1443-1448.
18. Paddison PJ, Hannon GJ (2002) RNA interference: the new somatic cell genetics? Cancer Cell 2: 17-23.
19. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, et al. (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 8: 769-776.
20. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, et al. (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21: 639-644.
21. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, et al. (2006) Prospects of RNA interference therapy for cancer. Gene Ther 13: 464-477.
22. Campochiaro PA (2006) Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13: 559-562.
23. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, et al. (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32: e49.
24. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL (2003) Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 305: 548-551.
25. Gallozzi M, Chapuis J, Le Provost F, Le Dur A, Morgenthaler C, et al. (2008) Prnp knockdown in transgenic mice using RNA interference. Transgenic Res 17: 783-791.
26. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
27. Lafon M (2005) Rabies virus receptors. J Neurovirol 11: 82-87.
28. Lentz TL, Burrage TG, Smith AL, Crick J, Tignor GH (1982) Is the acetylcholine receptor a rabies virus receptor? Science 215: 182-184.
29. Barichello JM, Ishida T, Kiwada H. Complexation of siRNA and pDNA with cationic liposomes: the important aspects in lipoplex preparation. Methods Mol Biol 605: 461-472.
30. Leng Q, Scaria P, Lu P, Woodle MC, Mixson AJ (2008) Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther 15: 485-495.
31. Leng Q, Woodle MC, Lu PY, Mixson AJ (2009) Advances in Systemic siRNA Delivery. Drugs Future 34: 721.
32. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007.
33. Rothdiener M, Muller D, Castro PG, Scholz A, Schwemmlein M, et al. Targeted delivery of siRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release.
34. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
35. Matveeva O, Nechipurenko Y, Rossi L, Moore B, Saetrom P, et al. (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 35: e63.
36. Hannon GJ (2002) RNA interference. Nature 418: 244-251.
37. Klohn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci U S A 100: 11666-11671.
38. Meyerett C, Michel B, Pulford B, Spraker TR, Nichols TA, et al. (2008) In vitro strain adaptation of CWD prions by serial protein misfolding cyclic amplification. Virology 382: 267-276.
39. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411: 810-813.
40. Nichols TA, Pulford B, Wyckoff AC, Meyerett C, Michel B, et al. (2009) Detection of protease-resistant cervid prion protein in water from a CWDendemic area. Prion 3: 171-183.
41. Zabel MD, Heikenwalder M, Prinz M, Arrighi I, Schwarz P, et al. (2007) Stromal Complement Receptor CD21/35 Facilitates Lymphoid Prion Colonization and Pathogenesis. J Immunol 179: 6144-6152.
42. D'Costa J, Mansfield SG, Humeau LM (2009) Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther 11: 554-564.
43. Dissen GA, Lomniczi A, Neff TL, Hobbs TR, Kohama SG, et al. (2009) In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods 49: 70-77.
44. Lundberg C, Bjorklund T, Carlsson T, Jakobsson J, Hantraye P, et al. (2008) Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8: 461-473.
45. Nanou A, Azzouz M (2009) Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 175: 187-200.
46. Valori CF, Ning K, Wyles M, Azzouz M (2008) Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr Gene Ther 8: 406-418.
47. Mulligan RC (1993) The basic science of gene therapy. Science 260: 926-932.
48. Lin K, Sadee W, Quillan JM (1999) Rapid measurements of intracellular calcium using a fluorescence plate reader. Biotechniques 26: 318-322, 324-316.
49. Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16: 869-871.
50. Mohuczy-Dominiak D, Garg LC (1992) Characterization of cholinergic receptors in Madin-Darby canine kidney cells. J Am Soc Nephrol 3: 170-181.
51. Nadler LS, Kumar G, Hinds TR, Migeon JC, Nathanson NM (1999) Asymmetric distribution of muscarinic acetylcholine receptors in Madin-Darby canine kidney cells. Am J Physiol 277: C1220-1228.
52. Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, et al. Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70: 896-905.
53. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, et al. (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3: 1-13.
54. Erin N, Wang N, Xin P, Bui V, Weisz J, et al. (2009) Altered gene expression in breast cancer liver metastases. Int J Cancer 124: 1503-1516.
55. Karapetyan YE, Saa P, Mahal SP, Sferrazza GF, Sherman A, et al. (2009) Prion strain discrimination based on rapid in vivo amplification and analysis by the cell panel assay. PLoS One 4: e5730.
56. Mahal SP, Baker CA, Demczyk CA, Smith EW, Julius C, et al. (2007) Prion strain discrimination in cell culture: the cell panel assay. Proc Natl Acad Sci U S A 104: 20908-20913.
57. Butler DA, Scott MR, Bockman JM, Borchelt DR, Taraboulos A, et al. (1988) Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol 62: 1558-1564.
58. Kim Y, Han B, Titlow W, Mays CE, Kwon M, et al. (2009) Utility of RNAimediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations. Antiviral Res 84: 185-193.
59. Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363-396.
60. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, et al. (1999) Lipid- DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163: 1552-1561.
61. Fairman J, Moore J, Lemieux M, Van Rompay K, Geng Y, et al. (2009) Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 5: 141-150.
62. Gowen BB, Fairman J, Dow S, Troyer R, Wong MH, et al. (2009) Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 81: 37-46.
63. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, et al. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176: 7335-7345.
64. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
65. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.
66. Kutscher HL, Chao P, Deshmukh M, Singh Y, Hu P, et al. (2010) Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release 143: 31-37.
67. Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, et al. (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53: 325-335.
68. Steele AD, Jackson WS, King OD, Lindquist S (2007) The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci U S A 104: 1983-1988.
69. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128-1132.
70. Fischer M, RÜlicke T, Raeber A, Sailer A, Moser M, et al. (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 15: 1255-1264.
71. Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, et al. (2008) The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS ONE 3: e3872.